Leukaemogenesis: more than mutant genes, Nature Reviews Cancer, vol.5, issue.1, pp.23-36, 2010. ,
DOI : 10.1038/nrc2765
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders, The Lancet, vol.365, issue.9464, pp.1054-1061, 2005. ,
DOI : 10.1016/S0140-6736(05)74230-6
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera, Nature, vol.100, issue.7037, pp.1144-1148, 2005. ,
DOI : 10.1182/blood-2002-09-2839
in Myeloproliferative Disorders, New England Journal of Medicine, vol.352, issue.17, pp.1779-1790, 2005. ,
DOI : 10.1056/NEJMoa051113
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis, Cancer Cell, vol.7, issue.4, pp.387-397, 2005. ,
DOI : 10.1016/j.ccr.2005.03.023
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr???Abl positive cells, Nature Medicine, vol.6, issue.5, pp.561-566, 1996. ,
DOI : 10.1038/376785a0
Mutations in Epigenetic Modifiers in Myeloid Malignancies and the Prospect of Novel Epigenetic-Targeted Therapy, Advances in Hematology, vol.116, issue.5 ,
DOI : 10.1186/1471-2407-10-197
Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases, Journal of Hematology & Oncology, vol.5, issue.1, p.12, 2012. ,
DOI : 10.1182/blood-2009-07-235358
URL : https://hal.archives-ouvertes.fr/inserm-00698796
Genetics of Myelodysplastic Syndromes: New Insights, Hematology, vol.2011, issue.1, pp.543-549, 2011. ,
DOI : 10.1182/asheducation-2011.1.543
Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications, Journal of Clinical Oncology, vol.29, issue.5, pp.475-486, 2011. ,
DOI : 10.1200/JCO.2010.30.2554
TET2, a tumor suppressor in hematological disorders, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1825, issue.2, pp.173-177, 2012. ,
DOI : 10.1016/j.bbcan.2011.12.002
Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F, Blood, vol.113, issue.9, pp.2022-2027, 2009. ,
DOI : 10.1182/blood-2008-07-167056
Current findings for recurring mutations in acute myeloid leukemia, Journal of Hematology & Oncology, vol.4, issue.1, p.36, 2011. ,
DOI : 10.1186/1756-8722-3-17
Mutations galore in myeloproliferative neoplasms: Would the real Spartacus please stand up?, Leukemia, vol.116, issue.7, pp.1059-1063, 2011. ,
DOI : 10.1084/jem.20090004
Mutations in Acute Myeloid Leukemia, Journal of Clinical Oncology, vol.29, issue.21, pp.2889-2896, 2011. ,
DOI : 10.1200/JCO.2011.35.4894
New mutations and pathogenesis of myeloproliferative neoplasms, Blood, vol.118, issue.7, pp.1723-1735, 2011. ,
DOI : 10.1182/blood-2011-02-292102
Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms, Blood Cancer Journal, vol.279, issue.8, p.18, 2011. ,
DOI : 10.1038/bcj.2011.31
in Myeloid Cancers, TET2 in myeloid cancers, pp.2289-2301, 2009. ,
DOI : 10.1056/NEJMoa0810069
250K Single Nucleotide Polymorphism Array Karyotyping Identifies Acquired Uniparental Disomy and Homozygous Mutations, Including Novel Missense Substitutions of c-Cbl, in Myeloid Malignancies, Cancer Research, vol.68, issue.24, pp.25010349-10357, 2008. ,
DOI : 10.1158/0008-5472.CAN-08-2754
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders, Nature Genetics, vol.8, issue.8, pp.722-726, 2010. ,
DOI : 10.1016/j.molcel.2008.10.016
in myelodysplastic syndromes and chronic myelomonocytic leukaemia, British Journal of Haematology, vol.279, issue.Suppl, pp.788-800, 2009. ,
DOI : 10.1111/j.1365-2141.2009.07697.x
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes, Nature Genetics, vol.647, issue.8, pp.665-667, 2010. ,
DOI : 10.1038/ng.414
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing, Nature, vol.115, issue.7382, pp.506-510, 2012. ,
DOI : 10.1038/nature10738
Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia, Blood, vol.118, issue.22, pp.5914-5917, 2011. ,
DOI : 10.1182/blood-2011-05-356204
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome, New England Journal of Medicine, vol.361, issue.11, pp.1058-1066, 2009. ,
DOI : 10.1056/NEJMoa0903840
Mutation in Myelodysplasia with Ring Sideroblasts, New England Journal of Medicine, vol.365, issue.15, pp.1384-1395, 2011. ,
DOI : 10.1056/NEJMoa1103283
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer, Nature Genetics, vol.73, issue.5, pp.521-523, 2009. ,
DOI : 10.1038/ng1950
SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts, Leukemia, vol.41, issue.3, pp.542-545, 2011. ,
DOI : 10.1038/leu.2011.232
Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia, Nature Genetics, vol.75, issue.4, pp.309-315, 2011. ,
DOI : 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
Frequent pathway mutations of splicing machinery in myelodysplasia, Nature, vol.451, issue.7367, pp.64-69, 2011. ,
DOI : 10.1038/nature10496
Array-based genomic resequencing of human leukemia, Oncogene, vol.2008, issue.25, pp.3723-3731, 2010. ,
DOI : 10.1182/blood.V97.8.2434
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A, Blood, vol.118, issue.14, pp.3932-3941, 2011. ,
DOI : 10.1182/blood-2010-10-311019
X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis, Blood, vol.107, issue.10, pp.4139-4141, 2006. ,
DOI : 10.1182/blood-2005-09-3900
The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera, Blood, vol.108, issue.6, pp.1865-1867, 2006. ,
DOI : 10.1182/blood-2006-01-013540
ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia, British Journal of Haematology, vol.114, issue.4, pp.1365-375, 2010. ,
DOI : 10.1111/j.1365-2141.2010.08381.x
URL : https://hal.archives-ouvertes.fr/hal-00580698
in myeloproliferative neoplasms, Genes, Chromosomes and Cancer, vol.478, issue.8, pp.743-755, 2012. ,
DOI : 10.1002/gcc.21960
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes, Blood, vol.119, issue.14, pp.3211-3218, 2012. ,
DOI : 10.1182/blood-2011-12-400994
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes, MJ: Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes, pp.53-57, 2011. ,
DOI : 10.1038/leu.2010.61
SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients, Leukemia, vol.3, issue.5, pp.1135-1137, 2011. ,
DOI : 10.1038/leu.2011.320
Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis, Blood, vol.119, issue.14, pp.3203-3210, 2012. ,
DOI : 10.1182/blood-2011-12-399774
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes, Blood, vol.119, issue.15, pp.3578-3584, 2012. ,
DOI : 10.1182/blood-2011-12-399337
Mutational Determinants of Epigenetic Instablity in Myeloid Malignancies, Seminars in Oncology, vol.39, issue.1, pp.80-96, 2012. ,
DOI : 10.1053/j.seminoncol.2011.11.006
Deletion of the tumor-suppressor gene NF1 occurs in 5% of myeloid malignancies and is accompanied by a mutation in the remaining allele in half of the cases, Leukemia, vol.26, issue.4, pp.834-839, 2011. ,
DOI : 10.1038/sj.leu.2404033
NF1 Inactivation in Adult Acute Myelogenous Leukemia, Clinical Cancer Research, vol.16, issue.16, pp.14135-4147, 2010. ,
DOI : 10.1158/1078-0432.CCR-09-2639
Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1genes, BMC Cancer, vol.46, issue.1, pp.299-314, 2008. ,
DOI : 10.1002/gcc.20426
Identification of recurring tumor-specific somatic mutations in acute myeloid leukemia by transcriptome sequencing, Leukemia, vol.54, issue.5, pp.821-827, 2011. ,
DOI : 10.1016/j.cell.2009.06.016
Gain of CBL-interacting protein, a possible alternative to CBL mutations in myeloid malignancies, Leukemia, vol.7, issue.8, pp.1539-1541, 2010. ,
DOI : 10.1038/ng.391
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms, Blood, vol.113, issue.24, pp.6182-6192, 2009. ,
DOI : 10.1182/blood-2008-12-194548
Family Members Constitute a Novel Common Pathogenic Lesion in Myeloid Malignancies, Journal of Clinical Oncology, vol.27, issue.36, pp.6109-6116, 2009. ,
DOI : 10.1200/JCO.2009.23.7503
Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms, Blood, vol.119, issue.5, pp.1208-1213, 2011. ,
DOI : 10.1182/blood-2011-07-367243
ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events, Genes, Chromosomes and Cancer, vol.49, issue.4, pp.328-337, 2012. ,
DOI : 10.1002/gcc.21918
Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia, Neoplasma, vol.59, issue.02, pp.168-174, 2012. ,
DOI : 10.4149/neo_2012_022
Transcription intermediary factor 1?? is a tumor suppressor in mouse and human chronic myelomonocytic leukemia, Journal of Clinical Investigation, vol.121, issue.6, pp.2361-2370, 2011. ,
DOI : 10.1172/JCI45213DS1
Chromosome 5q deletion and epigenetic suppression of the gene encoding ??-catenin (CTNNA1) in myeloid cell transformation, Nature Medicine, vol.66, issue.1, pp.78-83, 2007. ,
DOI : 10.1038/nm1512
Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome, British Journal of Haematology, vol.163, issue.2, pp.209-217, 2005. ,
DOI : 10.1038/88225
Clinical Applications of Epigenetic Markers and Epigenetic Profiling in Myeloid Malignancies, Seminars in Oncology, vol.39, issue.1, pp.109-122, 2012. ,
DOI : 10.1053/j.seminoncol.2011.11.003
Clinical Effect of Point Mutations in Myelodysplastic Syndromes, New England Journal of Medicine, vol.364, issue.26, pp.2496-2506, 2011. ,
DOI : 10.1056/NEJMoa1013343
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome, Nature, vol.99, issue.7218, pp.66-72, 2008. ,
DOI : 10.1038/nature07485
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression, Blood, vol.118, issue.1, pp.167-176, 2011. ,
DOI : 10.1182/blood-2011-01-331678
PHF6 mutations in adult acute myeloid leukemia, PHF6 mutations in adult acute myeloid leukemia, pp.130-134, 2011. ,
DOI : 10.1002/pbc.22574
Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia, Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia, pp.289-295, 2012. ,
DOI : 10.1038/sj.onc.1204646
Alteration of cohesin genes in myeloid diseases, American Journal of Hematology, vol.85, issue.9, pp.717-719, 2010. ,
DOI : 10.1002/ajh.21798
Transcriptional and epigenetic networks in haematological malignancy, FEBS Letters, vol.468, issue.13, pp.2100-2111, 2011. ,
DOI : 10.1016/j.febslet.2011.03.068
Epigenetic Mechanisms in Acute Myeloid Leukemia, Prog Drug Res, vol.67, pp.197-219, 2011. ,
DOI : 10.1007/978-3-7643-8989-5_10
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes, Nature, vol.6, issue.7279, pp.360-363, 2010. ,
DOI : 10.1038/nature08672
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma, Nature, vol.133, issue.7331, pp.539-542, 2011. ,
DOI : 10.1038/nature09639
Leukemic IDH1 and IDH2 Mutations Result in??a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation, Cancer Cell, vol.18, issue.6, pp.553-567, 2010. ,
DOI : 10.1016/j.ccr.2010.11.015
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate, Nature, vol.462, issue.7300, p.966, 2010. ,
DOI : 10.1038/nature09132
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting ??-Ketoglutarate to 2-Hydroxyglutarate, Cancer Cell, vol.17, issue.3, pp.225-234, 2010. ,
DOI : 10.1016/j.ccr.2010.01.020
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1, Science, vol.324, issue.5929, pp.930-935, 2009. ,
DOI : 10.1126/science.1170116
TET Family Proteins and Their Role in Stem Cell Differentiation and Transformation, Cell Stem Cell, vol.9, issue.3, pp.193-204, 2011. ,
DOI : 10.1016/j.stem.2011.08.007
Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine, Science, vol.333, issue.6047, pp.1300-1303, 2011. ,
DOI : 10.1126/science.1210597
TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity, Nature, vol.38, issue.7347, pp.343-348, 2011. ,
DOI : 10.1038/nature10066
Histone demethylation by a family of JmjC domain-containing proteins, Nature, vol.439, issue.7078, pp.811-816, 2006. ,
DOI : 10.1016/0160-5402(82)90004-3
Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation, Cancer Cell, vol.20, issue.1, pp.11-24, 2011. ,
DOI : 10.1016/j.ccr.2011.06.001
TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is??a Recurrent Event during Human Lymphomagenesis, TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis, pp.25-38, 2011. ,
DOI : 10.1016/j.ccr.2011.06.003
The Polycomb group protein EZH2 directly controls DNA methylation, Nature, vol.439, issue.7078, pp.871-874, 2006. ,
DOI : 10.1038/sj.emboj.7600509
Dnmt3a is essential for hematopoietic stem cell differentiation, Nature Genetics, vol.75, issue.1, pp.23-31, 2012. ,
DOI : 10.1182/blood-2007-11-126227
Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation, Nature, vol.10, issue.7347, pp.398-402, 2011. ,
DOI : 10.1038/nature10008
Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells, Nature, vol.18, issue.7347, pp.389-393, 2011. ,
DOI : 10.1038/nature09934
CTCF Regulates Allelic Expression of Igf2 by Orchestrating a Promoter-Polycomb Repressive Complex 2 Intrachromosomal Loop, Molecular and Cellular Biology, vol.28, issue.20, pp.6473-6482, 2008. ,
DOI : 10.1128/MCB.00204-08
Silencing chromatin: comparing modes and mechanisms, Nature Reviews Genetics, vol.438, issue.2, pp.123-135, 2011. ,
DOI : 10.1038/nrg2932
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia, Nature Medicine, vol.12, issue.2, pp.298-303, 2012. ,
DOI : 10.1038/leu.2011.93
-deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes, The Journal of Experimental Medicine, vol.209, issue.3, pp.445-454, 2012. ,
DOI : 10.1038/leu.2011.85
URL : https://hal.archives-ouvertes.fr/jpa-00254906
Alterations of polycomb gene BMI1 in human myeloproliferative neoplasms, Cell Cycle, vol.11, issue.16, 2012. ,
DOI : 10.1016/j.cancergencyto.2007.03.009
Mechanisms of Polycomb gene silencing: knowns and unknowns, Nature Reviews Molecular Cell Biology, vol.26, pp.697-708, 2009. ,
DOI : 10.1038/nrm2763
DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors, Papadopoulos N: DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors, pp.1199-1203, 2011. ,
DOI : 10.1126/science.1200609
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma, N: Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma, pp.226-231, 2012. ,
DOI : 10.1038/nature10833
Haplo-insufficiency: a driving force in cancer, The Journal of Pathology, vol.100, issue.2, pp.137-146, 2011. ,
DOI : 10.1002/path.2800
Myelodysplastic syndromes: lost between two states?, Leukemia, vol.647, issue.1, pp.1-5, 2010. ,
DOI : 10.1182/blood-2008-12-194548
Mammalian Polycomb-mediated repression of Hox genes requires the essential spliceosomal protein Sf3b1, Genes & Development, vol.19, issue.5, pp.536-541, 2005. ,
DOI : 10.1101/gad.1284605
Regulation of Alternative Splicing by Histone Modifications, Science, vol.327, issue.5968, pp.996-1000, 2010. ,
DOI : 10.1126/science.1184208
Genetic complexity of myeloproliferative neoplasms Leukemia, pp.1841-1848, 2008. ,
LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations, Leukemia, vol.118, issue.10, pp.1713-1718, 2010. ,
DOI : 10.1158/0008-5472.CAN-09-3783
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients, Blood, vol.108, issue.10, pp.3472-3476, 2006. ,
DOI : 10.1182/blood-2006-04-018879
Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias, Haematologica, vol.93, issue.10, pp.1595-1597, 2008. ,
DOI : 10.3324/haematol.13187
Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias, Leukemia, vol.24, issue.2, pp.469-473, 2010. ,
DOI : 10.1056/NEJMoa041974
Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias, BMC Cancer, vol.115, issue.1, pp.401-405, 2010. ,
DOI : 10.1182/blood-2009-07-230698
Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia, Blood, vol.118, issue.20, pp.5593-5603, 2011. ,
DOI : 10.1182/blood-2011-03-343988
Alterations of NFIA in chronic malignant myeloid diseases, Leukemia, vol.6, issue.3, pp.583-585, 2009. ,
DOI : 10.1016/S0301-472X(01)00789-5
Point mutations in myelodysplastic syndromes, N Engl J Med, vol.365, pp.1154-1155, 2011. ,
Murine Models of Human Acute Myeloid Leukemia, Cancer Treat Res, vol.145, pp.183-196, 2010. ,
DOI : 10.1007/978-0-387-69259-3_11
Animal models of acute myelogenous leukaemia ??? development, application and future perspectives, Leukemia, vol.21, issue.5, pp.687-706, 2005. ,
DOI : 10.1038/sj.leu.2403670
(1)F/TET2 mutations: does the order matter? Haematologica, pp.2-638, 2011. ,
Clonal Architecture of Secondary Acute Myeloid Leukemia, New England Journal of Medicine, vol.366, issue.12, pp.1090-1098, 2012. ,
DOI : 10.1056/NEJMoa1106968
Normal and leukemic hematopoiesis: Are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?, Proceedings of the National Academy of Sciences, vol.100, issue.Supplement 1, pp.11842-11849, 2003. ,
DOI : 10.1073/pnas.2034201100
In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm, Blood, vol.114, issue.14, pp.3018-3023, 2009. ,
DOI : 10.1182/blood-2009-03-209916
Molecular genetics of human leukemias: New insights into therapy, Seminars in Hematology, vol.39, issue.4, pp.6-11, 2002. ,
DOI : 10.1053/shem.2002.36921
JAK2 phosphorylates histone H3Y41 and excludes HP1?? from chromatin, Nature, vol.412, issue.7265, pp.819-822, 2009. ,
DOI : 10.1038/nature08448
Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes, Journal of Clinical Oncology, vol.29, issue.5, pp.504-515, 2011. ,
DOI : 10.1200/JCO.2010.31.1175
CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia, pp.198-206, 2011. ,
DOI : 10.1182/blood-2010-06-292433
Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia, Leukemia, vol.25, issue.10, pp.1661-1664, 2011. ,
DOI : 10.1038/leu.2010.65
Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group, Journal of Clinical Oncology, vol.28, issue.15, pp.2529-2537, 2010. ,
DOI : 10.1200/JCO.2009.23.4732
Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling, Oncogene, vol.23, issue.58, pp.9381-9391, 2004. ,
DOI : 10.1038/sj.onc.1207910
DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia, Cancer Cell, vol.17, issue.1, pp.13-27, 2010. ,
DOI : 10.1016/j.ccr.2009.11.020
High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression, Leukemia, vol.16, issue.6, pp.1139-1145, 2010. ,
DOI : 10.1073/pnas.95.21.12410
Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations, Blood, vol.116, issue.20, pp.4086-4094, 2010. ,
DOI : 10.1182/blood-2010-05-283291
Mutations in Patients With Myelodysplastic Syndromes, Journal of Clinical Oncology, vol.29, issue.18, pp.2499-2506, 2011. ,
DOI : 10.1200/JCO.2010.33.4938
Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes, Haematologica, vol.96, issue.10, pp.1462-1469, 2011. ,
DOI : 10.3324/haematol.2011.045591
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs), Blood, vol.114, issue.15, pp.23285-3291, 2009. ,
DOI : 10.1182/blood-2009-04-215814
Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study, Journal of Clinical Oncology, vol.29, issue.10, pp.21373-1381, 2011. ,
DOI : 10.1200/JCO.2010.32.7742
Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission, Blood, vol.116, issue.7, pp.1132-1135, 2010. ,
DOI : 10.1182/blood-2009-07-234484
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia, New England Journal of Medicine, vol.366, issue.12, pp.1079-1089, 2012. ,
DOI : 10.1056/NEJMoa1112304
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis, New England Journal of Medicine, vol.366, issue.9, pp.787-798, 2012. ,
DOI : 10.1056/NEJMoa1110556
Targeting myeloproliferative neoplasms with JAK inhibitors, Current Opinion in Hematology, vol.18, issue.2, pp.105-110, 2011. ,
DOI : 10.1097/MOH.0b013e3283439964
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis, New England Journal of Medicine, vol.366, issue.9, pp.799-807, 2012. ,
DOI : 10.1056/NEJMoa1110557
The Leukemogenicity of AML1-ETO Is Dependent on Site-Specific Lysine Acetylation, Science, vol.333, issue.6043, pp.765-769, 2011. ,
DOI : 10.1126/science.1201662
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias, Leukemia, vol.116, issue.7, pp.1147-1152, 2011. ,
DOI : 10.1038/ng.621
Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors, Hematological Oncology, vol.29, issue.3, pp.157-160, 2010. ,
DOI : 10.1002/hon.976
Biological validation that SF3b is a target of the antitumor macrolide pladienolide, FEBS Journal, vol.3, issue.Suppl 1, pp.4870-4880, 2011. ,
DOI : 10.1111/j.1742-4658.2011.08387.x
Reciprocal repression between P53 and TCTP, Nature Medicine, vol.9, issue.1, pp.91-99, 2012. ,
DOI : 10.1073/pnas.0400177101
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound, Nature Medicine, vol.8, issue.3, pp.282-288, 2002. ,
DOI : 10.1038/nm0302-282
Managing resistance in chronic myeloid leukemia, Blood Reviews, vol.25, issue.6, pp.279-290, 2011. ,
DOI : 10.1016/j.blre.2011.09.001
Harnessing synthetic lethal interactions in anticancer drug discovery, Nature Reviews Drug Discovery, vol.107, issue.5, pp.351-364, 2011. ,
DOI : 10.1038/nrd3374
Hypothesis: more mutations to cure cancer?, Oncology Reports, vol.6, pp.1189-1190, 1999. ,
DOI : 10.3892/or.6.6.1189